Novartis
NVS
1,028 hedge funds and large institutions have $22.4B invested in Novartis in 2018 Q3 according to their latest regulatory filings, with 91 funds opening new positions, 359 increasing their positions, 368 reducing their positions, and 44 closing their positions.
107% more first-time investments, than exits
New positions opened: 91 | Existing positions closed: 44
69% more funds holding in top 10
Funds holding in top 10: 13 → 22 (+9)
41% more call options, than puts
Call options by funds: $89.4M | Put options by funds: $63.6M
16% more capital invested
Capital invested by funds: $19.3B → $22.4B (+$3.11B)
4% more funds holding
Funds holding: 987 → 1,028 (+41)
0.2% more ownership
Funds ownership: 11.2% → 11.4% (+0.2%)
2% less repeat investments, than reductions
Existing positions increased: 359 | Existing positions reduced: 368
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$199M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$84M |
| 3 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$68.4M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$64.9M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$61.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$73.3M |
| 2 |
D.E. Shaw & Co
New York
|
-$70.6M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$53.7M |
| 4 |
Two Sigma Investments
New York
|
-$48.9M |
| 5 |
BBHC
Brown Brothers Harriman & Co
New York
|
-$44.3M |
NVS Hedge Fund Activity: Q3 2018 in Review
1,028 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q3 2018, worth a combined $22.4B — up 16% from $19.3B a quarter earlier.
Buyers outnumbered sellers: 91 funds opened new NVS positions and 44 closed out — a net gain of 47 holders — while 359 added to existing stakes and 368 trimmed.
The largest buyer was Arrowstreet Capital, adding an estimated $199M. The largest seller was Renaissance Technologies, cutting an estimated $73.3M.
- 1,028 institutional investors held Novartis (NVS) as of Q3 2018, up from 987 in Q2 2018.
- Funds reported $22.4B of Novartis stock for Q3 2018, up 16% quarter-over-quarter.
- 91 funds opened new Novartis positions in Q3 2018 and 44 closed out, a net change of +47 holders.
- The largest Novartis buyer in Q3 2018 was Arrowstreet Capital, an estimated $199M added.
- The largest Novartis seller in Q3 2018 was Renaissance Technologies, an estimated $73.3M sold.
Based on aggregated 13F filings for Q3 2018.